Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eupasidin-S vs Stillen in Gastritis
NCT02356679Phase 4Completed
- Sponsor
- Chong Kun Dang Holdings
- Start
- Aug 2014
- Primary completion
- Jun 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of eupatilin in gastritis (2 arms), sponsored by Chong Kun Dang Holdings. Primary endpoint: Cure rate of erosion at 2 weeks. Started Aug 2014; status: completed.
02
Drugs
eupatilin
03
Conditions
gastritis
Beyond the preview
Go deeper on NCT02356679.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02356679.